Copanlisib
Back to searchMolecule Structure
Scientific Name
Copanlisib
Description of the Drug
Copanlisib is a medication used to treat relapsed follicular lymphoma who have attempted at least two other treatments.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB12483
http://www.drugbank.ca/drugs/DB12483
Brand Name(s)
Not Available
Company Owner(s)
Bayer Healthcare Pharmaceuticals Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| PI3-kinase p110-delta subunit | SINGLE PROTEIN | INHIBITOR | CHEMBL3130 |
| PI3-kinase p110-alpha subunit | SINGLE PROTEIN | INHIBITOR | CHEMBL4005 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL1655478 | |
| DrugBank | DB12483 | |
| PubChem: Thomson Pharma | 56331049 | |
| Nikkaji | J3.452.228F | |
| PDBe | 6E2 | |
| BindingDB | 50204093 | |
| EPA CompTox Dashboard | DTXSID00145728 | |
| DrugCentral | 5256 | |
| ChemicalBook | CB52616024 | |
| Guide to Pharmacology | 7875 | |
| rxnorm | COPANLISIB | ALIQOPA |
| PubChem: Drugs of the Future | 136350052 | |
| ChEBI | 173077 | |
| ZINC | ZINC000068247389 |
